Olet poistumassa Viatris Suomen verkkosivustolta ja siirryt kolmannen osapuolen hallinnoimalle verkkosivustolle, jonka sisällöstä kolmas osapuoli vastaa. Linkit Viatrisin maakohtaisille sivustoille, sekä kolmansien osapuolten sivustoille on tarkoitettu vain lisätiedoksi asiakkaillemme. Otathan huomioon, että muilla Viatrisin maakohtaisilla sivustoilla saattaa esiintyä Suomen sivustosta poikkeavaa informaatiota, esimerkiksi sellaista paikalliseen lakiin ja sääntelyyn liittyvää tietoa, joka ei ole sovellettavissa Suomen liiketoiminta-alueelle. Otathan myös huomioon, että kolmansien osapuolten sivustoihin pätevät heidän omat käyttöehtonsa ja tietosuojakäytäntönsä - Viatris ei vastaa kolmansien osapuolten verkkosivustojen sisällöstä.
Unified by their commitment to helping patients address their evolving healthcare needs, our industry-leading team of executives and board members will guide Viatris into the future of global healthcare.
Executive management
Robert J. Coury
Executive Chairman
After leading the transformation of Mylan into one of the world's largest global pharmaceutical companies, Robert J. Coury again led the company to another level by combining forces with Upjohn to form Viatris, a new champion for global health. His strategic vision and leadership guide the company's performance and growth.
Viatris chief executive officer Scott A. Smith is a deeply knowledgeable senior global biotechnology and
pharmaceutical executive with more than 35 years of experience. He is a seasoned builder who
possesses vast global commercial and pharmaceutical expertise and a proven ability to build, grow and
manage large complex organizations. Before becoming Viatris’ CEO, Smith was President and Chief
Operating Officer of Celgene Corp. Most recently, he served as President of BioAtla, Inc., a global
biotechnology company focused on the development of Conditionally Active BiologicsTM (CAB) antibody
therapeutics. Smith is a member of Viatris board of directors.
Rajiv Malik began his pharmaceuticals career as a scientist and went on to become a leading pharmaceutical industry executive with more than 60 process patents to his name. His deep commercial, scientific and operational experience is an invaluable asset in his role as president of Viatris.
Sanjeev Narula was appointed as the chief financial officer of Viatris following 16 years of experience in senior financial leadership positions at Pfizer. He has a deep understanding of financial and commercial dynamics across geographies and in all Viatris markets.